TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Instagram Outage Disrupts Thousands of U.S. Users 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
LOS ANGELES, March 08, 2018 -- ViaDerma, Inc. (OTC Pink:VDRM), is pleased to provide an update of the Company’s current marketing activities:
- ViaDerma is in discussions with a Huntington Beach based international consulting firm, to explore placement of Vitastem in Infomercials, a nationwide pharmacy chain with 9600 stores domestically, and foreign placements throughout the Middle-East and Dubai.
- Discussions are also ongoing with representatives from a nationwide pharmaceutical distributor regarding distribution of Vitastem through their affiliated pharmacies and hospitals throughout the US, as well as distribution in the veterinary market though their association with veterinary suppliers nationwide.
- ViaDerma is awaiting a formal proposal from CMD Innovations, LLC, to use Vitastem in their wound healing protocol. CMD provides effective medical solutions for healthcare facilities including V.A. Hospitals.
- Negotiations are ongoing with a large, regional medical supply sales force for product distribution in pharmacies throughout the Southern United States.
- Vitastem is currently undergoing an approval process by government regulatory agencies in Nigeria and the Philippines. Upon approval, Vitastem will be distributed to hospitals in those countries and the Philippines prison system.
- Begun the process for approval of Vitastem by Medicare and other insurance companies reimbursement.
- ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
- Last month ViaDerma was a proud sponsor at “SB52 Big Game Event” held during Superbowl weekend in Minneapolis, organized by The Brewer Group, a marketing, media and consulting firm founded by former NFL player, Jack Brewer.
Dr. Christopher Otiko, President of ViaDerma, stated, “We are very excited in the direction we are headed with our product distribution efforts. We will provide further updates to these and other initiatives as developments unfold.”
About ViaDerma, Inc.
ViaDerma, Inc. (OTC:VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, visit: www.viadermalicensing.com
Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
Contact information:
Investor Relations
Email: [email protected]
Phone: 310-374-6111
